Published in Elife on January 05, 2016
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). ACS Med Chem Lett (2016) 0.77
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J Hematol Oncol (2016) 0.77
Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. J Biol Chem (2016) 0.76
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduct Target Ther (2017) 0.75
Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. Biochemistry (2016) 0.75
Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget (2017) 0.75
Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth. Mol Cell Proteomics (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
CBP/p300 in cell growth, transformation, and development. Genes Dev (2000) 10.76
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell (1998) 6.73
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 5.70
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J (2010) 3.25
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev (2000) 3.24
p300/CBP and cancer. Oncogene (2004) 3.13
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 3.13
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A (2012) 1.93
Transcriptional activation of immunoglobulin alpha heavy-chain genes by translocation of the c-myc oncogene. Nature (1983) 1.51
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (2011) 1.49
Multiple myeloma: biology of the disease. Blood Rev (2010) 1.35
Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res (2005) 1.34
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc (2014) 1.23
Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Cancer Res (1989) 1.02
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia (2014) 0.98
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res (2015) 0.97
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A (2015) 0.95
New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. Haematologica (2007) 0.86
The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene (2015) 0.85
Delineating domains and functions of NUP98 contributing to the leukemogenic activity of NUP98-HOX fusions. Leuk Res (2010) 0.81
A complex t(1;22;11)(q44;q13;q23) translocation causing MLL-p300 fusion gene in therapy-related acute myeloid leukemia. Eur J Haematol (2008) 0.80
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene (2015) 0.80